Loading...

MedXY AI/MedXY News/Tag: heart failure

MedXY News

EnglishTag

heart failure

147 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration

Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration

This review synthesizes findings from a 21- **Compiling final edits** Now that I’ve structured the article, I’m focusing on the final touches, particularly the content for the “Highlights,” “Expert Commentary,” and the “Conclusion” sections

Section: CardiologyMar 2, 2026

AKI and Diuretic Resistance: Identifying the High-Risk Phenotype in SCAI Stage B Cardiogenic Shock

AKI and Diuretic Resistance: Identifying the High-Risk Phenotype in SCAI Stage B Cardiogenic Shock

New research highlights that nearly a quarter of SCAI Stage B cardiogenic shock patients deteriorate. Acute kidney injury and diuretic resistance serve as critical early warning signs, providing clinicians a window for proactive interventio

Section: Cardiology

Mar 2, 2026

Restrictive Physiology, Not Systolic Failure, Defines the Clinical Landscape of Cardiac Amyloidosis

Restrictive Physiology, Not Systolic Failure, Defines the Clinical Landscape of Cardiac Amyloidosis

A large-scale study identifies restrictive physiology as the dominant phenotype in cardiac amyloidosis. While preserved function offers better survival, rapid progression to restriction underscores the importance of early diagnosis and moni

Section: CardiologyMar 2, 2026

Heart Failure Prevention in Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT-2 and DPP-4 Inhibitors

Heart Failure Prevention in Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT-2 and DPP-4 Inhibitors

A large-scale target trial emulation demonstrates that GLP-1RAs significantly reduce heart failure hospitalization risks compared to DPP-4 inhibitors and provide comparable protection to SGLT-2 inhibitors in routine clinical practice.

Section: Clinical UpdatesMar 2, 2026

AI-Enabled Stethoscopes in Primary Care: Why Implementation Science Matters More Than Algorithm Accuracy

AI-Enabled Stethoscopes in Primary Care: Why Implementation Science Matters More Than Algorithm Accuracy

The TRICORDER trial demonstrates that while AI stethoscopes are capable of detecting heart failure, atrial fibrillation, and valvular disease, their real-world implementation in UK primary care did not yield a statistically significant incr

Section: AIMar 2, 2026

Healing the Heart with Tradition: The Promise of the MUTTON-HF Program in the Navajo Nation

Healing the Heart with Tradition: The Promise of the MUTTON-HF Program in the Navajo Nation

A groundbreaking clinical trial demonstrates that medically tailored meals featuring traditional Indigenous foods can significantly improve heart failure outcomes and food security in rural Navajo communities.

Section: CardiologyFeb 24, 2026

Beyond Blood Sugar: Why Insulin Resistance Drives Vagal Dysfunction in Heart Failure

Beyond Blood Sugar: Why Insulin Resistance Drives Vagal Dysfunction in Heart Failure

Evidence from the Myovasc study reveals that insulin resistance and C-peptide levels are independent predictors of impaired cardiac vagal activity in heart failure, suggesting that metabolic health directly influences autonomic regulation b

Section: CardiologyFeb 4, 2026

Insulin Metabolism as a Primary Driver of Cardiac Autonomic Dysfunction in Heart Failure: Insights from the Myovasc Study

Insulin Metabolism as a Primary Driver of Cardiac Autonomic Dysfunction in Heart Failure: Insights from the Myovasc Study

The Myovasc study demonstrates that insulin resistance and secretion markers, rather than glucose levels alone, are independently associated with impaired cardiac vagal activity in heart failure patients, suggesting a metabolic-autonomic ax

Section: CardiologyFeb 4, 2026

AI-ECG Models for Heart Failure Screening Show High Accuracy in First-of-its-Kind Independent Comparison Study

AI-ECG Models for Heart Failure Screening Show High Accuracy in First-of-its-Kind Independent Comparison Study

This independent validation study confirms that AI-enhanced ECG models effectively detect left ventricular systolic dysfunction across diverse populations, achieving AUROCs up to 0.93. However, significant barriers remain regarding model tr

Section: AIJan 26, 2026

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

This study identifies key plasma biomarkers—including NT-proBNP, FGF-23, and GDF-15—that predict heart failure hospitalization in patients with atrial fibrillation. Findings also reveal distinct pathophysiological pathways for HFrEF and HFp

Section: CardiologyJan 22, 2026

Precision Lead Placement: How 4D Phenomics Digital Heart Models are Revolutionizing Cardiac Resynchronization Therapy

Precision Lead Placement: How 4D Phenomics Digital Heart Models are Revolutionizing Cardiac Resynchronization Therapy

The MAPIT-CRT trial demonstrates that using 4D cardiac MRI-generated digital heart models to guide lead placement significantly improves LVEF in heart failure patients compared to standard techniques, offering a safe and feasible precision

Section: CardiologyJan 21, 2026

Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER

Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER

A critical reanalysis of the DAPA-HF and DELIVER trials reveals that the survival proportional odds model provides greater statistical power and more robust treatment effect estimates than traditional Cox regression in heart failure populat

Section: CardiologyJan 19, 2026

Prediabetes and Silent Cardiac Injury: A High-Risk Synergy for Heart Failure in Hypertensive Patients

Prediabetes and Silent Cardiac Injury: A High-Risk Synergy for Heart Failure in Hypertensive Patients

A post hoc analysis of the SPRINT trial reveals that the coexistence of prediabetes and subclinical myocardial injury or stress significantly escalates heart failure risk in hypertensive adults, suggesting a need for integrated glycemic and

Section: CardiologyJan 18, 2026

Is Indefinite Heart Failure Therapy Necessary After AF Rhythm Control? Insights from the WITHDRAW-AF Trial

Is Indefinite Heart Failure Therapy Necessary After AF Rhythm Control? Insights from the WITHDRAW-AF Trial

The WITHDRAW-AF trial suggests that heart failure therapy can be safely withdrawn in patients with atrial fibrillation-mediated cardiomyopathy who achieve rhythm control and ejection fraction normalization, showing no significant decline in

Section: CardiologyJan 18, 2026

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline

Section: CardiologyJan 17, 2026

Finerenone Provides Robust Protection Against Heart Failure Events Regardless of Baseline NYHA Functional Class

Finerenone Provides Robust Protection Against Heart Failure Events Regardless of Baseline NYHA Functional Class

A prespecified analysis of the FINEARTS-HF trial confirms that finerenone reduces cardiovascular death and heart failure events in patients with HFmrEF and HFpEF across all symptomatic stages, offering the greatest absolute benefit to those

Section: CardiologyJan 17, 2026

Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF

Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF

This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase

Section: CardiologyJan 17, 2026

Reversing Prediabetes Halves 30-Year Risk of Cardiovascular Death and Heart Failure: New Insights from DPPOS and DaQing

Reversing Prediabetes Halves 30-Year Risk of Cardiovascular Death and Heart Failure: New Insights from DPPOS and DaQing

A landmark post-hoc analysis of the DPPOS and DaQing studies reveals that achieving prediabetes remission reduces the risk of cardiovascular death and heart failure hospitalization by approximately 50% over three decades, highlighting a pro

Section: CardiologyJan 7, 2026

Baseline Risk Does Not Resuscitate PCI Benefit in Ischemic Cardiomyopathy: Lessons from the REVIVED-BCIS2 Sub-analysis

Baseline Risk Does Not Resuscitate PCI Benefit in Ischemic Cardiomyopathy: Lessons from the REVIVED-BCIS2 Sub-analysis

A prespecified analysis of the REVIVED-BCIS2 trial reveals that baseline risk of death or hospitalization does not modify the effectiveness of PCI in patients with ischemic left ventricular dysfunction, reinforcing the primacy of optimal me

Section: CardiologyJan 4, 2026

High-Acuity Presentations with Favorable Outcomes: The Paradox of Young Adults in the Cardiac ICU

High-Acuity Presentations with Favorable Outcomes: The Paradox of Young Adults in the Cardiac ICU

A large-scale registry study reveals that young adults (18-39) in the Cardiac Intensive Care Unit present with higher rates of cardiogenic shock and cardiac arrest compared to older adults, yet demonstrate significantly higher survival rate

Section: CardiologyJan 4, 2026

Prev 1 2 3 4 5 6 8 Next